Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)

ClinicalTrials.gov ID: NCT00684177

Public ClinicalTrials.gov record NCT00684177. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Multicenter, Placebo-controlled, Phase III Superiority Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adult and Pediatric Subjects With SITL

Study identification

NCT ID
NCT00684177
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
508 participants

Conditions and interventions

Interventions

  • Retapamulin Ointment, 1% Drug
  • Placebo ointment Drug

Drug

Eligibility (public fields only)

Age range
2 Months and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2008
Primary completion
Sep 30, 2009
Completion
Sep 30, 2009
Last update posted
Nov 22, 2016

2008 – 2009

United States locations

U.S. sites
32
U.S. states
16
U.S. cities
30
Facility City State ZIP Site status
GSK Investigational Site Tucson Arizona 85705
GSK Investigational Site Anaheim California 92804
GSK Investigational Site Fresno California 93710
GSK Investigational Site Irvine California 90620
GSK Investigational Site Los Angeles California 90048
GSK Investigational Site Sacramento California 95825
GSK Investigational Site Colorado Springs Colorado 80904
GSK Investigational Site Deerfield Beach Florida 33441
GSK Investigational Site Hollywood Florida 33023
GSK Investigational Site Miami Florida 33144
GSK Investigational Site Miami Florida 33155
GSK Investigational Site Orlando Florida 32712
GSK Investigational Site Panama City Florida 32401
GSK Investigational Site Tampa Florida 33606
GSK Investigational Site Vero Beach Florida 32960
GSK Investigational Site West Palm Beach Florida 33401
GSK Investigational Site Arlington Heights Illinois 60005
GSK Investigational Site Kansas City Kansas 66160
GSK Investigational Site New Orleans Louisiana 70112
GSK Investigational Site Butte Montana 59701
GSK Investigational Site Teaneck New Jersey 07666
GSK Investigational Site Brooklyn New York 11218
GSK Investigational Site Brooklyn New York 11229
GSK Investigational Site East Syracuse New York 13057
GSK Investigational Site Johnson City New York 13790
GSK Investigational Site Cincinnati Ohio 45246
GSK Investigational Site Norristown Pennsylvania 19401
GSK Investigational Site Uniontown Pennsylvania 15401
GSK Investigational Site Greenville South Carolina 29615
GSK Investigational Site Houston Texas 77036
GSK Investigational Site Bountiful Utah 84010
GSK Investigational Site Vienna Virginia 22180

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00684177, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 22, 2016 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00684177 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →